Health Care & Life Sciences » Pharmaceuticals | IntelGenx Technologies Corp.

IntelGenx Technologies Corp. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
5,005.00
4,399.00
2,865.00
4,496.00
4,904.00
10,995
Total Accounts Receivable
412.00
760.00
1,237.00
1,290.00
937.00
1,231
Other Current Assets
133.00
96.00
70.00
566.00
203.00
462
Total Current Assets
5,550.00
5,255.00
4,172.00
6,352.00
6,044.00
13,063
Net Property, Plant & Equipment
588.00
983.00
4,238.00
5,730.00
6,346.00
6,248
Total Investments and Advances
-
-
506.00
708.00
757.00
-
Intangible Assets
-
46.00
-
-
-
-
Other Assets
79.00
-
-
-
-
707
Total Assets
6,217.00
6,284.00
8,916.00
12,790.00
13,147.00
20,018
ST Debt & Current Portion LT Debt
-
-
184.00
704.00
772.00
Accounts Payable
12.00
102.00
1,595.00
897.00
1,305.00
Other Current Liabilities
889.00
1,609.00
0.00
3,634.00
-
Total Current Liabilities
901.00
1,711.00
1,779.00
5,235.00
2,077.00
Long-Term Debt
-
-
1,546.00
2,565.00
7,191.00
Other Liabilities
308.00
-
27.00
45.00
50.00
Total Liabilities
1,209.00
1,711.00
3,352.00
7,845.00
9,318.00
Common Equity (Total)
5,008.00
4,573.00
5,564.00
4,945.00
3,829.00
Total Shareholders' Equity
5,008.00
4,573.00
5,564.00
4,945.00
3,829.00
Total Equity
5,008.00
4,573.00
5,564.00
4,945.00
3,829.00
Liabilities & Shareholders' Equity
6,217.00
6,284.00
8,916.00
12,790.00
13,147.00

About IntelGenx Technologies

View Profile
Address
6420 Abrams
Ville Saint-Laurent Québec H4S 1X9
Canada
Employees -
Website http://www.intelgenx.com
Updated 07/08/2019
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast. It also offers a comprehensive portfolio of pharmaceutical services, such as pharmaceutical research and development, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing.